Log in to save to my catalogue

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A...

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1673954391

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

About this item

Full title

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

Publisher

United States: Public Library of Science

Journal title

PloS one, 2015-04, Vol.10 (4), p.e0120427-e0120427

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood p...

Alternative Titles

Full title

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_1673954391

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1673954391

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0120427

How to access this item